Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Dynastat opvejer risiciene ved kortvarig behandling af smerter efter operation.
The Committee for Medicinal Products for Human Use (CHMP) decided that Dynastat’ s benefits are greater than its risks for the short-term treatment of postoperative pain.